Rezolute Drug Meets Phase 3 Endpoint in Tumor Trial
Ersodetug met the primary endpoint in a phase 3 trial for tumor hyperinsulinism, and the company plans talks with the FDA about a potential filing.
Updated on Nov. 13, 2026 in Diabetes

Rezolute's phase 3 Uplift trial of ersodetug in tumor hyperinsulinism met its primary endpoint, with 13 of 16 enrolled patients meeting the responder criterion of a 50% or greater reduction in glucose infusion rate. The company's shares opened 10% higher in premarket trading on Friday.
Why it matters
The positive result could strengthen the case for ersodetug in congenital hyperinsulinism, which the FDA has advised Rezolute to discuss with agency staff before filing for approval. Analysts at Guggenheim said the tumor data could validate the congenital hyperinsulinism case.
In the phase 3 Uplift trial, 13 of 16 enrolled patients reached the responder threshold of at least a 50% reduction in glucose infusion rate, and 12 stopped IV glucose entirely. Three participants remain in the pivotal period, and the trial's long-term durability has not yet been reported.
The players
Rezolute
Rezolute is a biopharmaceutical company developing ersodetug for hyperinsulinism disorders.
Guggenheim
Guggenheim is a global investment bank whose analysts follow biotechnology companies and commented on the trial results.
U.S. Food and Drug Administration
The FDA is the federal agency that reviews and approves drugs for sale in the United States.
The details
Patients had to have been on IV glucose infusion or parenteral nutrition for at least seven days to join the trial. One patient dropped out early and died one week later of cancer progression, and no drug-related safety findings were attributed to ersodetug.
Timeline
Oct. 5: Guggenheim analysts noted positive tumor data could validate the congenital hyperinsulinism case.
Oct. 14: Guggenheim analysts called a positive trial outcome highly likely.
Thursday: Rezolute closed at $3.87 per share.
Friday: Rezolute shares opened 10% higher at $4.27 in premarket trading.
First quarter of next year: Rezolute plans to meet with FDA staff regarding a potential filing.
Health Landscape
The FDA has asked Rezolute to meet with agency staff before seeking approval in congenital hyperinsulinism, a rare disorder that causes dangerously low blood sugar in infants. Positive data from the tumor form of the disease could add supporting evidence to the congenital form's regulatory case.
For families affected by congenital hyperinsulinism, a filing could eventually lead to a new treatment option that reduces the need for IV glucose. Any approval would depend on FDA review of the trial data and the regulatory discussions still ahead.
The takeaway
A single positive trial can open a regulatory conversation, but the path from a phase 3 result to an approved therapy still depends on FDA review. Readers tracking hyperinsulinism treatments should watch for updates on the planned agency meeting.
What happens next
Rezolute plans to meet with FDA staff in the first quarter of next year to discuss a potential filing for ersodetug.
Further reading
Explore more Diabetes coverage for context on insulin-related conditions and treatments.






